Samsung Pharmaceutical Co., Ltd. (KOSE:A001360) announced a private placement of unregistered and unsecured private convertible bonds for gross proceeds of KRW 14,500,000,000 on October 19, 2015. The company will issue 25th unregistered unsecured unguaranteed private convertible bonds for KRW 3,300,000,000 and 26th unregistered unsecured unguaranteed private convertible bonds for KRW 11,200,000,000. The bonds will be issued at par.

Each bond will mature on October 23, 2018. The bonds issued will carry yield to maturity of 4% and zero coupon rate. The lump sum redemption will take place at the time of maturity.

Each bond will be convertible into the common shares of the company at KRW 14,007 per share. There will be 100% conversion. The conversion period will start on October 23, 2016 and end on September 23, 2018.

The subscription date for the bonds is October 21, 2015 and the payment date is October 23, 2015. The transaction will include participation from 30 investors for 26th series bonds, including returning investor, GemVax Technology Co., Ltd. for KRW 2,000,000,000, new investors, Hankang Life Co., Ltd. for KRW 1,000,000,000, Kwang-Soon Park for KRW 1,000,000,000, Aju Savings Bank, Investment Arm for KRW 1,000,000,000, and others. The transaction will include participation from a new investor, Tae-Ho Kim for 25th series bonds.

The transaction has been approved by the board of directors of the company.